Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free BPCR Stock Alerts

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.94 0.00 (-0.21%)
As of 05:35 AM Eastern
Compare

BPCR vs. FWT, SGEM, JARA, NBMI, and CBA

Should you buy BioPharma Credit stock or one of its competitors? MarketBeat compares BioPharma Credit with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioPharma Credit include Foresight Technology VCT (FWT), ScotGems (SGEM), JPMorgan Global Core Real Assets (JARA), NB Global Monthly Income Fund Ltd GBP (NBMI), and Ceiba Investments (CBA). These companies are all part of the "asset management" industry.

How does BioPharma Credit compare to Foresight Technology VCT?

Foresight Technology VCT (LON:FWT) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

BioPharma Credit has higher revenue and earnings than Foresight Technology VCT. Foresight Technology VCT is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foresight Technology VCT-£2.30M-18.73£23.15M-£7.45N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.08

Foresight Technology VCT has a net margin of 127.75% compared to BioPharma Credit's net margin of 92.62%. BioPharma Credit's return on equity of 11.29% beat Foresight Technology VCT's return on equity.

Company Net Margins Return on Equity Return on Assets
Foresight Technology VCT127.75% -7.25% 3.17%
BioPharma Credit 92.62%11.29%4.98%

In the previous week, Foresight Technology VCT's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Foresight Technology VCT Neutral
BioPharma Credit Neutral

Foresight Technology VCT has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.2134515, meaning that its stock price is 79% less volatile than the broader market.

27.0% of BioPharma Credit shares are held by institutional investors. 0.3% of Foresight Technology VCT shares are held by company insiders. Comparatively, 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioPharma Credit beats Foresight Technology VCT on 9 of the 11 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

ScotGems (LON:SGEM) and BioPharma Credit (LON:BPCR) are both small-cap asset management industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

27.0% of BioPharma Credit shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioPharma Credit has a net margin of 92.62% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
ScotGemsN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

In the previous week, ScotGems' average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
ScotGems Neutral
BioPharma Credit Neutral

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScotGems£5.07M0.00N/A£0.07N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.08

ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 744.7%. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

BioPharma Credit beats ScotGems on 9 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to JPMorgan Global Core Real Assets?

BioPharma Credit (LON:BPCR) and JPMorgan Global Core Real Assets (LON:JARA) are both small-cap financial services companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

27.0% of BioPharma Credit shares are held by institutional investors. Comparatively, 7.6% of JPMorgan Global Core Real Assets shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Comparatively, 0.6% of JPMorgan Global Core Real Assets shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioPharma Credit has a net margin of 92.62% compared to JPMorgan Global Core Real Assets' net margin of 77.28%. BioPharma Credit's return on equity of 11.29% beat JPMorgan Global Core Real Assets' return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
JPMorgan Global Core Real Assets 77.28%5.64%-3.14%

In the previous week, JPMorgan Global Core Real Assets had 5 more articles in the media than BioPharma Credit. MarketBeat recorded 5 mentions for JPMorgan Global Core Real Assets and 0 mentions for BioPharma Credit. BioPharma Credit's average media sentiment score of 0.00 beat JPMorgan Global Core Real Assets' score of -0.57 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Neutral
JPMorgan Global Core Real Assets Negative

BioPharma Credit has higher revenue and earnings than JPMorgan Global Core Real Assets. BioPharma Credit is trading at a lower price-to-earnings ratio than JPMorgan Global Core Real Assets, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
JPMorgan Global Core Real Assets£8.07M5.22-£4.51M£2.1935.83

BioPharma Credit has a beta of 0.2134515, indicating that its stock price is 79% less volatile than the broader market. Comparatively, JPMorgan Global Core Real Assets has a beta of 0.087, indicating that its stock price is 91% less volatile than the broader market.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 744.7%. JPMorgan Global Core Real Assets pays an annual dividend of GBX 1.05 per share and has a dividend yield of 1.3%. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. JPMorgan Global Core Real Assets pays out 47.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

BioPharma Credit beats JPMorgan Global Core Real Assets on 10 of the 15 factors compared between the two stocks.

How does BioPharma Credit compare to NB Global Monthly Income Fund Ltd GBP?

BioPharma Credit (LON:BPCR) and NB Global Monthly Income Fund Ltd GBP (LON:NBMI) are both small-cap financial services companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

BioPharma Credit has a net margin of 92.62% compared to NB Global Monthly Income Fund Ltd GBP's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat NB Global Monthly Income Fund Ltd GBP's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
NB Global Monthly Income Fund Ltd GBP N/A N/A N/A

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled NB Global Monthly Income Fund Ltd GBP'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
NB Global Monthly Income Fund Ltd GBP Neutral

27.0% of BioPharma Credit shares are held by institutional investors. Comparatively, 44.3% of NB Global Monthly Income Fund Ltd GBP shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Comparatively, 0.2% of NB Global Monthly Income Fund Ltd GBP shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 744.7%. NB Global Monthly Income Fund Ltd GBP pays an annual dividend of GBX 9 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. NB Global Monthly Income Fund Ltd GBP pays out 5,294.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioPharma Credit has higher revenue and earnings than NB Global Monthly Income Fund Ltd GBP. NB Global Monthly Income Fund Ltd GBP is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
NB Global Monthly Income Fund Ltd GBPN/AN/AN/A£0.17N/A

Summary

BioPharma Credit beats NB Global Monthly Income Fund Ltd GBP on 7 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to Ceiba Investments?

Ceiba Investments (LON:CBA) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Ceiba Investments has a net margin of 6,890.36% compared to BioPharma Credit's net margin of 92.62%. BioPharma Credit's return on equity of 11.29% beat Ceiba Investments' return on equity.

Company Net Margins Return on Equity Return on Assets
Ceiba Investments6,890.36% -25.40% 2.31%
BioPharma Credit 92.62%11.29%4.98%

In the previous week, Ceiba Investments' average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Ceiba Investments Neutral
BioPharma Credit Neutral

1.4% of Ceiba Investments shares are owned by institutional investors. Comparatively, 27.0% of BioPharma Credit shares are owned by institutional investors. 47.7% of Ceiba Investments shares are owned by company insiders. Comparatively, 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioPharma Credit has higher revenue and earnings than Ceiba Investments. Ceiba Investments is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ceiba Investments-£39.52M-1.04£8.64M-£30.00N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.08

Ceiba Investments has a beta of 0.227, meaning that its stock price is 77% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.2134515, meaning that its stock price is 79% less volatile than the broader market.

Summary

BioPharma Credit beats Ceiba Investments on 8 of the 11 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

Export
MetricBioPharma CreditAsset Management IndustryFinancial SectorLON Exchange
Market Cap£10.57M£2.37B£5.70B£2.75B
Dividend Yield7.46%5.99%5.27%6.07%
P/E Ratio0.0825.2116.02365.93
Price / Sales0.082,084.581,291.1488,337.70
Price / Cash1.1960.1790.6127.89
Price / Book0.011.354.387.70
Net Income£10.42B£265.53M£1.15B£5.89B
7 Day PerformanceN/A-0.28%0.23%0.42%
1 Month PerformanceN/A2.42%2.03%2.10%
1 Year Performance8.05%13.23%21.48%86.90%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.94
-0.2%		N/A+6.6%£10.57M£132.06M0.08N/A
FWT
Foresight Technology VCT
N/AGBX 88
flat		N/AN/A£42.20M-£2.30MN/A375
SGEM
ScotGems
N/AN/AN/AN/A£42.02M£5.07M1,121.43N/A
JARA
JPMorgan Global Core Real Assets
N/AGBX 77.01
flat		N/A+2.6%£41.30M£8.07M35.17N/A
NBMI
NB Global Monthly Income Fund Ltd GBP
N/AN/AN/AN/A£41.02MN/A338.24N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCR) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel